Zepbound (tirzepatide) / Eli Lilly - LARVOL DELTA

Probable tirzepatide-associated limbic encephalitis with status epilepticus in a patient with extreme obesity: a case report. (PubMed, Neurol Sci) - No abstract available

Journal • CNS Disorders • Epilepsy • Genetic Disorders • Obesity

Tirzepatide as adjunct therapy in patients with type 1 diabetes: a systematic review and meta-analysis. (PubMed, J Diabetes Metab Disord) - "This review aims to evaluate the efficacy of tirzepatide as an adjunct to insulin therapy in adults with Type 1 diabetes mellitus (T1DM) and overweight or obesity, focusing on changes in glycemic control, body weight, body mass index (BMI), and insulin dose requirements...Larger randomized controlled trials are warranted to confirm these results and define optimal dosing and long-term safety. The online version contains supplementary material available at 10.1007/s40200-026-01880-0."

Journal • Retrospective data • Anorexia • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (clinicaltrials.gov) - P3 | N=441 | Completed | Sponsor: Eli Lilly and Company | Active, not recruiting ➔ Completed | Trial completion date: May 2026 ➔ Jan 2026 | Trial primary completion date: May 2026 ➔ Jan 2026

Trial completion • Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

Safety and Effectiveness of Tirzepatide in Patients With Obesity at Hospital de Clínicas, Paraguay (clinicaltrials.gov) - P=N/A | N=300 | Not yet recruiting | Sponsor: LABORATORIOS INDUFAR

New trial • Diabetes • Endocrine Disorders • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

EFFECTS OF INCRETIN-BASED THERAPIES ON KIDNEY OUTCOMES IN OBESE PATIENTS WITHOUT DIABETES (ISN-WCN 2026) - "Consistent findings across frequentist and Bayesian analyses strengthened result robustness.Conclusion Among obese adults without diabetes, Retatrutide produced the largest improvement in eGFR, while Semaglutide and Retatrutide most effectively reduced UACR. Incretin-based therapies may confer renal benefits beyond glycemic control, supporting further evaluation of dual GLP-1/GIP agonists in nondiabetic obesity-related kidney disease."

Clinical • Cardiovascular • Diabetes • Diabetic Nephropathy • Genetic Disorders • Inflammation • Metabolic Disorders • Nephrology • Obesity • Renal Disease • Type 2 Diabetes Mellitus • RAS

TIRZEPATIDE FOR RESISTANT HYPERTENSION IN NON-DIABETIC IGA NEPHROPATHY (ISN-WCN 2026) - "SGLT2 inhibitors and spironolactone were previously discontinued due to recurrent balanoposthitis and hyperkalemia...BP normalized dramatically (200/100→118/70 mmHg, 82/30 mmHg reduction), achieving KDIGO targets and enabling 50% medication reduction (6→3 drugs: discontinued minoxidil, prazosin, clonidine; continued telmisartan, chlorthalidone, cilnidipine)...This represents a paradigm shift toward metabolic intervention in proteinuric non-diabetic CKD with obesity and resistant hypertension. GLP-1 receptor agonists merit investigation as cornerstone therapies alongside RAAS inhibitors and SGLT2 inhibitors, particularly in advanced fibrosis where immunosuppression risks may outweigh benefits."

Cardiovascular • Chronic Kidney Disease • Diabetic Nephropathy • Fibrosis • Genetic Disorders • Glomerulonephritis • Hypertension • IgA Nephropathy • Immunology • Lupus Nephritis • Obesity • Renal Disease

ASSOCIATION OF TIRZEPATIDE WITH KIDNEY PARAMETERS IN PEOPLE WITH OBESITY AND PREDIABETES FROM SURMOUNT-1 OVER 176 WEEKS (ISN-WCN 2026) - P3 | "A significantly smaller decline in eGFR was observed with pooled TZP (-1.6±0.5 ml/min per 1.73m2) compared to placebo (-5.5±1.0 ml/min per 1.73m2) after 176 weeks (estimated treatment difference (ETD) of 3.9 ml/min per 1.73m2, p<0.001). A greater percentage decrease in UACR was observed with pooled TZP (-15.8±2.9%) compared to placebo (-3.9±6.4%) after 176 weeks (ETD of -12.4%, p=0.078).Conclusion In SURMOUNT-1 participants with prediabetes, overweight or obesity, and preserved eGFR at baseline, use of TZP was associated with an attenuated decline of eGFR over 3 years with a nonsignificant trend toward UACR reduction.This abstract was also submitted for the American Diabetes Association – 85th Annual Scientific Sessions, Chicago, IL, USA, in 2025.I have potential conflict of interest to disclose.Yusuke Takahashi is an employee of Eli Lilly Japan K.K. and a minor stockholder of Eli Lilly and Company.I did not use generative AI and AI-assisted..."

Chronic Kidney Disease • Diabetic Nephropathy • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. (PubMed, Diabetes Obes Metab) - "Lean mass loss during significant weight reduction is substantial, and the proportion of weight lost as lean mass is broadly comparable between incretin-based pharmacotherapy and lifestyle interventions. Muscle mass can be significantly preserved by integrating resistance training, adequate protein intake, and body composition monitoring into weight-loss treatment programs."

Journal • Retrospective data • Genetic Disorders • Obesity

Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis. (PubMed, Am J Med) - P3 | "In this post hoc analysis of SURMOUNT-5, a greater proportion of tirzepatide-treated participants in both responder groups achieved all body weight reduction thresholds vs semaglutide. Although rapid responders experienced more gastrointestinal/hepatobiliary adverse events in both treatments, this did not affect rates of study treatment completion relative to non-rapid responders."

Journal • Retrospective data • Genetic Disorders • Obesity

The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity (clinicaltrials.gov) - P4 | N=40 | Recruiting | Sponsor: Mayo Clinic | Active, not recruiting ➔ Recruiting | Initiation date: Sep 2025 ➔ Apr 2026

Enrollment open • Trial initiation date • Genetic Disorders • Obesity

Sleep-Related Outcomes in Patients with OSA Treated with Tirzepatide for Obesity or Overweight via Telehealth (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Clinical • Metabolic Disorders • Obesity

Effect of Tirzepatide on Cardiac Arrhythmia in Adults with Type 2 Diabetes and Obesity: A Systematic Review and Meta-Analysis (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Retrospective data • Review • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Oral Delivery of Semaglutide, Tirzepatide, and Retatrutide Formulated in Polymerized Ursodeoxycholic Acid (pUDCA) Nanoparticles (NP) (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Metabolic Disorders

Real-World Outcomes of Tirzepatide Combined with Personalized Lifestyle Modification in an Indian Population with Diabetes and Obesity (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Clinical • Real-world • Real-world evidence • Diabetes • Metabolic Disorders • Obesity

Tirzepatide Induced Cardiometabolic Transformation in Indian Patients with Obesity: A Prospective Cohort Study (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Clinical • Metabolic Disorders • Obesity

Tirzepatide Enhances Metabolic Outcomes in People with Type 1 Diabetes and Overweight/Obesity: A Retrospective Cohort Study at Sydney's Royal North Shore Hospital (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Retrospective data • Diabetes • Metabolic Disorders • Obesity • Type 1 Diabetes Mellitus

Guidelines for the diagnosis and treatment of obstructive sleep apnea in adults (2025) (PubMed, Zhonghua Jie He He Hu Xi Za Zhi) - "For patients with residual EDS despite adequate and adherent OSA therapy, treatment with solriamfetol or modafinil is recommended to improve daytime sleepiness (1, A)...Remote diagnostic pathways combining HSAT with electronic questionnaires may be considered (2, B). Quality control measures should be implemented to ensure safety and effectiveness (1, A)."

Journal • Acromegaly • Addiction (Opioid and Alcohol) • Alzheimer's Disease • Asthma • Cardiovascular • Chronic Cough • Chronic Obstructive Pulmonary Disease • CNS Disorders • Cognitive Disorders • Congestive Heart Failure • Cough • Depression • Diabetes • Endocrine Disorders • Excessive Daytime Sleepiness • Genetic Disorders • Heart Failure • Hypertension • Immunology • Insomnia • Metabolic Disorders • Obesity • Obstructive Sleep Apnea • Oncology • Pain • Polycystic Ovary Syndrome • Psychiatry • Pulmonary Disease • Respiratory Diseases • Sleep Disorder • Tobacco Cessation • Type 2 Diabetes Mellitus • Vascular Neurology • Xerostomia

Renal Outcomes of GLP-1 Receptor Agonists and Tirzepatide Across CKD Stages and Metabolic Phenotypes (Type 2 Diabetes and/or Overweight/Obesity): A Scoping Review. (PubMed, Diabetes Ther) - "GLP-1-based therapies demonstrate consistent renoprotective signals across CKD stages and metabolic phenotypes, particularly in type 2 diabetes. Evidence is strongest for semaglutide and dulaglutide, with emerging data for tirzepatide and other incretin-based agents. These findings provide a structured evidence map to inform future consensus and clinical decision-making."

Journal • Review • Cardiovascular • Chronic Kidney Disease • Diabetes • Genetic Disorders • Metabolic Disorders • Nephrology • Obesity • Renal Disease • Type 2 Diabetes Mellitus

MANAGING MULTIFACTORIAL CHYLOMICRONEMIA THROUGH TEAM-BASED CARDIOMETABOLIC CARE: A REAL-WORLD CASE (ACC 2026) - "Background: Multifactorial chylomicronemia syndrome (MCS) is characterized by severe hypertriglyceridemia driven by polygenic susceptibility and secondary factors such as obesity, diet, and metabolic disease...Initial triglycerides (TG) were 1,752 mg/dL while on statin, fenofibrate micronized, icosapent ethyl, and a thiazide diuretic...Multidisciplinary adjustments included dietary reinforcement and addition of evolocumab, reducing TG to 430 mg/dL, followed by initiation of tirzepatide after complex prior authorization... Sustained MCS control requires a multifaceted, team-based approach addressing lifestyle, pharmacotherapy, and systemic challenges. Coordinated cardiometabolic care achieves lasting TG reduction and mitigates long-term cardiovascular and pancreatitis risk."

Clinical • Real-world • Real-world evidence • Cardiovascular • Dyslipidemia • Genetic Disorders • Hypertension • Hypertriglyceridemia • Metabolic Disorders • Obesity • Obstructive Sleep Apnea • Pancreatitis • Respiratory Diseases • Severe Hypertriglyceridemia • Sleep Disorder

Risk of Developing Scarring and Non-Scarring Alopecia with GLP-1 and GLP-1/GIP Agonist Utilization (AAD 2026) - "The treatment cohort included patients who initially used semaglutide, liraglutide, exenatide, dulaglutide, or tirzepatide after 2017. Treated patients were matched 1:1 with non-treated controls based on age, sex, race, type 2 diabetes, and congestive heart failure using propensity score matching...The treatment cohort had a significantly increased risk of developing all alopecia diagnoses (p < 0.0001), including the development of alopecia areata, androgenic alopecia, central centrifugal cicatricial alopecia, lichen planopilaris, frontal fibrosing alopecia, and folliculitis decalvans. These findings suggest GLP-1 and GLP-1/GIP agonists may significantly increase the risk of developing scarring and non-scarring alopecia."

Alopecia • Cardiovascular • Congestive Heart Failure • Dermatopathology • Diabetes • Fibrosis • Heart Failure • Hypertension • Immunology • Lichen Planus • Metabolic Disorders • Type 2 Diabetes Mellitus

Impact of GLP-1 and Dual GLP-1/GIP Receptor Agonists on Inflammatory Outcomes in Atopic Dermatitis: A Real-World Cohort Study (AAD 2026) - "Background: GLP-1 receptor agonists are established injectable therapies used in diabetes and obesity... These results support prior reports that GLP-1 receptor agonists reduce skin inflammation in AD. By attenuating NF-κB signaling and suppressing TNF-α, IL-6, and IL-17, GLP-1 agonists reduce inflammation. GIP signaling in tirzepatide may enhance this effect by decreasing adipose inflammation and limiting immune activation."

Clinical • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Diabetes • Genetic Disorders • Immunology • Inflammation • Metabolic Disorders • Obesity • Pruritus • Urticaria • IL17A • IL6 • TNFA

GLP-1 receptor agonists-associated skin events: identifying the most common culprits and reactions (AAD 2026) - "Several patients (42%) experienced over three comorbidities, with diabetes, obesity, and hypertension being most common...Out of total alopecia reports, 700 (30.2%) were associated with semaglutide, 534 (23.1%) with liraglutide, 492 (21.3%) with tirzepatide, 304 (13.1%) with dulaglutide, and 284 (12.3%) with exenatide...GLP-1 RAs are associated with various dermatologic AEs, ranging from mild rashes to autoimmune disease. Increased recognition can improve diagnostic accuracy and guide safe therapeutic substitutions."

Alopecia • Cardiovascular • Diabetes • Genetic Disorders • Hypertension • Immunology • Metabolic Disorders • Obesity • Pruritus • Urticaria

Dermatological effects of GLP-1 receptor agonists: A literature review (AAD 2026) - "Glucagon-like peptide-1 (GLP-1) receptor agonists have become an increasingly common class of medications for the management of type 2 diabetes mellitus and obesity...Improvement in psoriasis was reported with liraglutide, semaglutide, and exenatide...Our review demonstrates the dual nature of the dermatological effects of these medications. Clinicians should be made aware of these effects and monitor patients when prescribing GLP-1 receptor agonists."

Review • Acne Vulgaris • Alopecia • Atopic Dermatitis • Bullous Pemphigoid • Constipation • Dermatopathology • Diabetes • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Hidradenitis Suppurativa • Immunology • Inflammatory Arthritis • Lupus • Metabolic Disorders • Obesity • Pruritus • Psoriasis • Type 2 Diabetes Mellitus • Vasculitis

Dermatologic side effects of GLP-1 receptor agonists: A Cross-sectional Analysis (AAD 2026) - "Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used for the management of diabetes and obesity, with gastrointestinal side effects being the most commonly reported...Search terms included: GLP-1 Receptor Agonist, Semaglutide, Tirzepatide, Liraglutide, Dulaglutide, Exenatide, Lixisenatide, Albiglutide... Dermatologic AEs due to GLP-1 RAs use are relatively uncommon. Injection-site reactions represent the most frequent cutaneous complication, while alopecia, dermatitis, and urticaria are rarely reported. Proactively anticipating and addressing these dermatologic AEs are essential to optimizing patient care and counseling."

Adverse events • Alopecia • Dermatitis • Diabetes • Genetic Disorders • Immunology • Metabolic Disorders • Obesity • Pruritus • Urticaria

Impact of GLP-1 and GLP-1/GIP Agonists on Health Care Utilization in Individuals with Psoriasis: A Retrospective Cohort Analysis (AAD 2026) - "The treatment cohort included patients receiving semaglutide, liraglutide, or tirzepatide within one year of psoriasis diagnosis. Patients were matched 1:1 with non-treated controls based on age, sex, race, ethnicity, BMI, type 2 diabetes, congestive heart failure, and systemic psoriasis therapies using propensity score matching...The treated cohort averaged 8.87 hospitalizations and 2.53 ER visits per patient versus 13.70 and 3.14, respectively, in controls. These findings suggest GLP-1 and GLP-1/GIP agonists may reduce healthcare resource utilization in psoriasis, potentially reflecting improved disease control and financial burden."

HEOR • Retrospective data • Cardiovascular • Congestive Heart Failure • Dermatology • Dermatopathology • Diabetes • Heart Failure • Immunology • Metabolic Disorders • Psoriasis • Type 2 Diabetes Mellitus • IL12A • IL17A • IL23A